These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12410858)

  • 41. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
    J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
    Herman WH; Shahinfar S; Carides GW; Dasbach EJ; Gerth WC; Alexander CM; Cook JR; Keane WF; Brenner BM
    Diabetes Care; 2003 Mar; 26(3):683-7. PubMed ID: 12610022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
    Bichu P; Nistala R; Khan A; Sowers JR; Whaley-Connell A
    Vasc Health Risk Manag; 2009; 5(1):129-40. PubMed ID: 19436679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
    McMullan CJ; Lambers Heerspink HJ; Parving HH; Dwyer JP; Forman JP; de Zeeuw D
    Am J Kidney Dis; 2014 Nov; 64(5):714-22. PubMed ID: 25064674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
    de Zeeuw D; Ramjit D; Zhang Z; Ribeiro AB; Kurokawa K; Lash JP; Chan J; Remuzzi G; Brenner BM; Shahinfar S
    Kidney Int; 2006 May; 69(9):1675-82. PubMed ID: 16572114
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
    Rasi Hashemi S; Noshad H; Tabrizi A; Mobasseri M; Tayebi Khosroshahi H; Heydarnejad M; Khalaj MR; Aghamohammadzadeh N
    Iran J Kidney Dis; 2012 Jan; 6(1):39-43. PubMed ID: 22218118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
    Imai E; Chan JC; Ito S; Yamasaki T; Kobayashi F; Haneda M; Makino H;
    Diabetologia; 2011 Dec; 54(12):2978-86. PubMed ID: 21993710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.
    Keane WF; Brenner BM; de Zeeuw D; Grunfeld JP; McGill J; Mitch WE; Ribeiro AB; Shahinfar S; Simpson RL; Snapinn SM; Toto R;
    Kidney Int; 2003 Apr; 63(4):1499-507. PubMed ID: 12631367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
    Fried LF; Emanuele N; Zhang JH; Brophy M; Conner TA; Duckworth W; Leehey DJ; McCullough PA; O'Connor T; Palevsky PM; Reilly RF; Seliger SL; Warren SR; Watnick S; Peduzzi P; Guarino P;
    N Engl J Med; 2013 Nov; 369(20):1892-903. PubMed ID: 24206457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Miao Y; Dobre D; Heerspink HJ; Brenner BM; Cooper ME; Parving HH; Shahinfar S; Grobbee D; de Zeeuw D
    Diabetologia; 2011 Jan; 54(1):44-50. PubMed ID: 20882268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
    Miao Y; Ottenbros SA; Laverman GD; Brenner BM; Cooper ME; Parving HH; Grobbee DE; Shahinfar S; de Zeeuw D; Lambers Heerspink HJ
    Hypertension; 2011 Jul; 58(1):2-7. PubMed ID: 21632472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
    Alexander CM; Lyle PA; Keane WF; Carides GW; Zhang Z; Shahinfar S
    Kidney Int Suppl; 2004 Nov; (92):S115-7. PubMed ID: 15485403
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.
    Keane WF; Zhang Z; Lyle PA; Cooper ME; de Zeeuw D; Grunfeld JP; Lash JP; McGill JB; Mitch WE; Remuzzi G; Shahinfar S; Snapinn SM; Toto R; Brenner BM;
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):761-7. PubMed ID: 17699284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteinuric renal disease in type 2 diabetes-is remission of proteinuria associated with improved mortality and morbidity?
    Tan J; Jaung R; Gamble G; Cundy T
    Diabetes Res Clin Pract; 2014 Jan; 103(1):63-70. PubMed ID: 24380605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
    Mohanram A; Zhang Z; Shahinfar S; Keane WF; Brenner BM; Toto RD
    Kidney Int; 2004 Sep; 66(3):1131-8. PubMed ID: 15327408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.
    Parving HH; Mogensen CE; Thomas MC; Brenner BM; Cooper ME
    QJM; 2005 Feb; 98(2):119-26. PubMed ID: 15655096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.